Our study provides evidence that baseline systemic inflammation markers, particularly C-reactive protein-to-lymphocyte ratio (CLR) and lactate dehydrogenase (LDH), serve as robust prognostic biomarkers in PD-L1-negative advanced NSCLC patients receiving the multimodal BRICS sequential regimen. This evidence concerns the gene CD274 and non-small cell lung carcinoma.